{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:24:54Z","timestamp":1790436294081,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"15","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>The purpose of this review is to discuss infectious disease\u2013related adverse effects associated with long-term proton pump inhibitor (PPI) therapy in patients with cirrhosis and to provide recommendations for appropriate use and choice of PPI when such therapy is indicated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Long-term PPI therapy in patients with cirrhosis increases the risk of infections, with infections in turn increasing the risk of mortality in this patient population. Expert recommendations include restricting long-term PPI use in cirrhosis to patients with appropriate gastrointestinal indications, using a PPI for the shortest possible duration and at the lowest possible dose, and avoiding PPIs with unfavorable pharmacogenetic properties.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Long-term PPI use in patients with cirrhosis has been associated with increased infections. The risk of adverse effects in observational studies, including decompensation, severe infection (especially spontaneous bacterial peritonitis), and increased mortality, appears to increase as the dose and duration of PPI increase.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxad089","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T01:09:56Z","timestamp":1682644196000},"page":"967-973","source":"Crossref","is-referenced-by-count":6,"title":["Infection risk and management strategies for patients with cirrhosis taking proton pump inhibitors"],"prefix":"10.1093","volume":"80","author":[{"given":"Beth","family":"Zerr","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Arizona R. Ken Coit College of Pharmacy , Phoenix, AZ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Vazquez","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Arizona R. Ken Coit College of Pharmacy , Phoenix, AZ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L","family":"Erstad","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Arizona R. Ken Coit College of Pharmacy , Tucson, AZ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"issue":"6","key":"2023072218484897500_CIT0001","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1002\/hep.28812","article-title":"Time trends in the health care burden and mortality of acute on chronic liver failure in the United States","volume":"64","author":"Allen","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"2023072218484897500_CIT0002","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2018.10.027","article-title":"Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe","volume":"70","author":"Fern\u00e1ndez","year":"2019","journal-title":"J Hepatol"},{"issue":"24","key":"2023072218484897500_CIT0003","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMra2021808","article-title":"The evolving challenge of infections in cirrhosis","volume":"384","author":"Bajaj","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"2023072218484897500_CIT0004","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4254\/wjh.v8.i6.307","article-title":"Bacterial infections in cirrhosis: a critical review and practical guidance","volume":"8","author":"Bunchorntavakul","year":"2016","journal-title":"World J Hepatol"},{"issue":"3","key":"2023072218484897500_CIT0005","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5056\/jnm.2011.17.3.287","article-title":"Effects of histamine-2 receptor antagonists and proton pump inhibitors on the rate of gastric emptying: a crossover study using a continuous real-time C breath test (BreathID System)","volume":"17","author":"Nonaka","year":"2011","journal-title":"J Neurogastroenterol Motil"},{"issue":"8266","key":"2023072218484897500_CIT0006","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(82)90974-6","article-title":"Aspiration of gastric bacteria in antacid-treated patients: a frequent cause of postoperative colonisation of the airway","volume":"1","author":"du Moulin","year":"1982","journal-title":"Lancet"},{"issue":"10","key":"2023072218484897500_CIT0007","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/apt.12694","article-title":"The use of proton pump inhibitors and the spectrum and number of biliary pathogens in patients with acute cholangitis","volume":"39","author":"Schneider","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2023072218484897500_CIT0008","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jamainternmed.2020.0009","article-title":"Evaluation of the association between gastric acid suppression and risk of intestinal colonization with multidrug-resistant microorganisms: a systematic review and meta-analysis","volume":"180","author":"Willems","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"12","key":"2023072218484897500_CIT0009","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1161\/CIRCRESAHA.116.308807","article-title":"Proton pump inhibitors accelerate endothelial senescence","volume":"118","author":"Yepuri","year":"2016","journal-title":"Circ Res"},{"issue":"3","key":"2023072218484897500_CIT0010","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"issue":"6","key":"2023072218484897500_CIT0011","doi-asserted-by":"crossref","first-page":"e015735","DOI":"10.1136\/bmjopen-2016-015735","article-title":"Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans","volume":"7","author":"Xie","year":"2017","journal-title":"BMJ Open"},{"issue":"1","key":"2023072218484897500_CIT0012","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2022.03.052","article-title":"The association between proton pump inhibitor exposure and key liver-related outcomes in patients with cirrhosis: a Veterans Affairs cohort study","volume":"163","author":"Mahmud","year":"2022","journal-title":"Gastroenterology"},{"issue":"3","key":"2023072218484897500_CIT0013","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12072-019-10010-3","article-title":"Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and meta-analysis","volume":"14","author":"Wang","year":"2020","journal-title":"Hepatol Int"},{"issue":"1","key":"2023072218484897500_CIT0014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.5152\/tjg.2022.20689","article-title":"Correlation between proton pump inhibitors and the complications of liver cirrhosis: a systematic review and meta-analysis","volume":"33","author":"Hwang","year":"2022","journal-title":"Turk J Gastroenterol"},{"issue":"3","key":"2023072218484897500_CIT0015","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.4238\/2015.July.3.25","article-title":"Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis","volume":"14","author":"Xu","year":"2015","journal-title":"Genet Mol Res"},{"issue":"4","key":"2023072218484897500_CIT0016","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.dld.2015.12.009","article-title":"Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: a meta-analysis","volume":"48","author":"Yu","year":"2016","journal-title":"Dig Liver Dis"},{"issue":"6","key":"2023072218484897500_CIT0017","doi-asserted-by":"crossref","first-page":"BSR20193890","DOI":"10.1042\/BSR20193890","article-title":"Proton pump inhibitor use and mortality in patients with cirrhosis: a meta-analysis of cohort studies","volume":"40","author":"Wu","year":"2020","journal-title":"Biosci Rep"},{"issue":"5","key":"2023072218484897500_CIT0018","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/apt.13061","article-title":"Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis","volume":"41","author":"Dultz","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2023072218484897500_CIT0019","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jgh.12065","article-title":"Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis","volume":"28","author":"Deshpande","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"2023072218484897500_CIT0020","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/MEG.0000000000000448","article-title":"Systematic review and meta-analysis of the possible association between pharmacological gastric acid suppression and spontaneous bacterial peritonitis","volume":"27","author":"Khan","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"2023072218484897500_CIT0021","doi-asserted-by":"crossref","first-page":"244","DOI":"10.14309\/ajg.0000000000000061","article-title":"Patients\u2019 perceptions of proton pump inhibitor risks and attempts at discontinuation: a national survey","volume":"114","author":"Kurlander","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2023072218484897500_CIT0022","doi-asserted-by":"crossref","first-page":"689","DOI":"10.14309\/ajg.0000000000000558","article-title":"Physicians\u2019 perceptions of proton pump inhibitor risks and recommendations to discontinue: a national survey","volume":"115","author":"Kurlander","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2023072218484897500_CIT0023","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/MEG.0b013e3282f4aa01","article-title":"Inadequate use of proton-pump inhibitors in patients with liver cirrhosis","volume":"20","author":"Kalaitzakis","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"2023072218484897500_CIT0024","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2021.12.247","article-title":"AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review","volume":"162","author":"Targownik","year":"2022","journal-title":"Gastroenterology"},{"key":"2023072218484897500_CIT0025","author":"Prilosec OTC","year":"2021"},{"key":"2023072218484897500_CIT0026","author":"Nexium 24Hr OTC","year":"2022"},{"key":"2023072218484897500_CIT0027","author":"Prevacid 24 Hr OTC","year":"2021"},{"issue":"5","key":"2023072218484897500_CIT0028","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40265-017-0712-6","article-title":"The safety of appropriate use of over-the-counter proton pump inhibitors: an evidence-based review and Delphi consensus","volume":"77","author":"Johnson","year":"2017","journal-title":"Drugs"},{"issue":"12","key":"2023072218484897500_CIT0029","doi-asserted-by":"crossref","first-page":"e0243134","DOI":"10.1371\/journal.pone.0243134","article-title":"Impact of pharmacy-supported interventions on proportion of patients receiving non-indicated acid suppressive therapy upon discharge: a systematic review and meta-analysis","volume":"15","author":"Singh-Franco","year":"2020","journal-title":"PLoS One"},{"key":"2023072218484897500_CIT0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejim.2016.10.007","article-title":"The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal","volume":"37","author":"Savarino","year":"2017","journal-title":"Eur J Intern Med"},{"issue":"1","key":"2023072218484897500_CIT0031","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13063-022-06232-w","article-title":"Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial","volume":"23","author":"Wehmeyer","year":"2022","journal-title":"Trials"},{"issue":"8","key":"2023072218484897500_CIT0032","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/bcp.13615","article-title":"Safe use of proton pump inhibitors in patients with cirrhosis","volume":"84","author":"Weersink","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2023072218484897500_CIT0033","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40264-017-0635-x","article-title":"Evidence-based recommendations to improve the safe use of drugs in patients with liver cirrhosis","volume":"41","author":"Weersink","year":"2018","journal-title":"Drug Saf"},{"key":"2023072218484897500_CIT0034","author":"Lansoprazole. Prescribing information. Takeda Pharmaceuticals America","year":"2023"},{"key":"2023072218484897500_CIT0035","author":"Pantoprazole","year":"2023"},{"issue":"6","key":"2023072218484897500_CIT0036","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of proton pump inhibitors","volume":"10","author":"Shin","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"key":"2023072218484897500_CIT0037","author":"Nexium","year":"2014"},{"key":"2023072218484897500_CIT0038","author":"Aciphex","year":"2014"},{"key":"2023072218484897500_CIT0039","author":"Plavix","year":"2021"},{"issue":"2","key":"2023072218484897500_CIT0040","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0016-5085(99)70118-6","article-title":"Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status","volume":"116","author":"Gillen","year":"1999","journal-title":"Gastroenterology"},{"issue":"21","key":"2023072218484897500_CIT0041","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.3390\/ijms20215469","article-title":"Problems associated with deprescribing of proton pump inhibitors","volume":"20","author":"Helgadottir","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2023072218484897500_CIT0042","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2036.2006.03084.x","article-title":"Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial","volume":"24","author":"Bj\u00f6rnsson","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2023072218484897500_CIT0043","first-page":"e15022","article-title":"A randomized open-label study of two methods of proton pump inhibitors discontinuation","volume":"13","author":"Hendricks","year":"2021","journal-title":"Cureus"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxad089\/50422349\/zxad089.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/15\/967\/50931123\/zxad089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/15\/967\/50931123\/zxad089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T18:49:10Z","timestamp":1690051750000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/80\/15\/967\/7146179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":43,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,4,27]]},"published-print":{"date-parts":[[2023,7,21]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxad089","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,4,27]]}}}